Trial Profile
An Open-label Phase IIa, Non-randomized Study of Alpharadin in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Pharmacodynamics
- Sponsors Bayer HealthCare Pharmaceuticals
- 09 Feb 2012 Primary endpoint 'N-telopeptide-of-the-cross-links-of-collagen' has been met.
- 09 Feb 2012 Primary endpoint 'Alkaline-phosphatase-levels' has been met.
- 09 Dec 2011 Results presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium and published in an Algeta media release.